References
- BayraktarZAlacaliNBayraktarSDiabetic papillopathy in type II diabetic patientsRetina200222675275812476102
- RegilloCDBrownGCSavinoPJByrnesGABensonWETasmanWSSergottRCDiabetic papillopathy. Patient characteristics and fundus findingsArch Ophthalmol199511378898957605280
- HayrehSSZimmermanBNonarteritic anterior ischemic optic neuropathy: clinical characteristics in diabetic patients versus nondiabetic patientsOphthalmology2008115101818182518502511
- KimMLeeJHLeeSJDiabetic papillopathy with macular edema treated with intravitreal ranibizumabClin Ophthalmol201372257226024348012
- Al-HinaiASAl-AbriMSAl-HajriRHDiabetic papillopathy with macular edema treated with intravitreal bevacizumabOman J Ophthalmol20114313513822279402
- Al-HaddadCEJurdiFABashshurZFIntravitreal triamcinolone acetonide for the management of diabetic papillopathyAm J Ophthalmol200413761151115315183815
- LubowMMakleyTAJrPseudopapilledema of juvenile diabetes mellitusArch Ophthalmol19718544174225554869
- AppenREChandraSRKleinRMyersFLDiabetic papillopathyAm J Ophthalmol19809022032097425031
- OtoSYilmazGCakmakciAAydinPIndocyanine green and fluorescein angiography in nonarteritic anterior ischemic optic neuropathyRetina200222218719111927852
- WeisSMChereshDAPathophysiological consequences of VEGF-induced vascular permeabilityNature2005437705849750416177780